Drug
Tocilizumab (Actemra®)
Tocilizumab (Actemra®) is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_2
1
50%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Other(1)
Detailed Status
unknown1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 21 (100.0%)
Trials by Status
unknown150%
recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingphase_2
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
NCT07334379
unknown
Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis
NCT03288584
Clinical Trials (2)
Showing 2 of 2 trials
NCT07334379Phase 2
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
NCT03288584
Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2